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Abstract
Myotubularins (MTMs) are active or dead phosphoinositides phosphatases defining a large protein family conserved through
evolution and implicated in different neuromuscular diseases. Loss-of-function mutations in MTM1 cause the severe congenital
myopathy called myotubular myopathy (or X-linked centronuclear myopathy) while mutations in the MTM1-related protein
MTMR2 cause a recessive Charcot-Marie-Tooth peripheral neuropathy. Here we aimed to determine the functional specificity
and redundancy of MTM1 and MTMR2, and to assess their abilities to compensate for a potential therapeutic strategy. Using
molecular investigations and heterologous expression of human MTMs in yeast cells and in Mtm1 knockout mice, we character-
ized several naturally occurring MTMR2 isoforms with different activities. We identified the N-terminal domain as responsi-
ble for functional differences between MTM1 and MTMR2. An N-terminal extension observed in MTMR2 is absent in MTM1, and
only the short MTMR2 isoform lacking this N-terminal extension behaved similarly to MTM1 in yeast and mice. Moreover,
adeno-associated virus-mediated exogenous expression of several MTMR2 isoforms ameliorates the myopathic phenotype ow-
ing to MTM1 loss, with increased muscle force, reduced myofiber atrophy, and reduction of the intracellular disorganization
hallmarks associated with myotubular myopathy. Noteworthy, the short MTMR2 isoform provided a better rescue when com-
pared with the long MTMR2 isoform. In conclusion, these results point to the molecular basis for MTMs functional specificity.
They also provide the proof-of-concept that expression of the neuropathy-associated MTMR2 gene improves the MTM1-
associated myopathy, thus identifying MTMR2 as a novel therapeutic target for myotubular myopathy.
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Introduction
Myotubularin (MTM1) and MTM-related proteins (MTMR) define
a conserved protein family implicated in different neuromuscu-
lar diseases (1). They have been classified in the phosphatase
super-family. In humans, eight MTMs share the C(X)5R motif
found in tyrosine and dual-specificity phosphatases and display
enzymatic activity, while the six others lack this motif and are
nicknamed dead-phosphatases. Unexpectedly, it was found
that enzymatically active MTMs do not act on proteins but de-
phosphorylate phosphoinositides (PPIn), lipids concentrated in
specific membrane sub-domains (2,3). PPIn are lipid second
messengers implicated in a wide range of cellular processes in-
cluding signaling and intracellular organization (4). MTMs are
PPIn 3-phosphatases that dephosphorylate the phosphatidyli-
nositol (PtdIns) 3-phosphate (PtdIns3P) and the PtdIns
3,5-bisphosphate (PtdIns(3,5)P2), leading to the production of
PtdIns5P (2,3,5–7). PtdIns5P is implicated in transcriptional
regulation and growth factor signaling, while PtdIns3P and
PtdIns(3,5)P2 regulate membrane trafficking and autophagy.
PtdIns3P is produced through the phosphorylation of PtdIns by
class II and III PtdIns 3-kinases and PtdIns(3,5)P2 is obtained
mainly from the phosphorylation of PtdIns3P by PIKfyve (8,9).
They recruit proteins to specific endosomal pools or to particu-
lar endoplasmic reticulum sites where autophagosomes are
formed. For example, the Fab1-YOTB-Vac1-EEA1 (FYVE) domain
of EEA1 binds specifically PtdIns3P concentrated on early endo-
somes to regulate endosomal fusion and cargo delivery (9).
Dead MTMs oligomerize with and regulate the enzymatic ac-
tivity and/or subcellular localization of their active homologs
(10–12). In addition to the active or dead phosphatase domain,
MTMs share a Pleckstrin Homology, Glucosyltransferase, Rab-
like GTPase Activator and MTM (PH-GRAM) domain that bind to
PPIn or proteins, and a coiled-coil domain implicated in their
oligomerization (1).
There are 14 MTMs in human and one active MTM in yeast
Saccharomyces cerevisiae (1,13). The yeast MTM Ymr1 regulates
vacuole protein sorting and its absence induces vacuolar frag-
mentation (14). Expression of human MTM1 in yeast leads to
the enlargement of the vacuole as a consequence of its phos-
phatase activity and PtdIns3P decrease (2,15). In human, muta-
tions in MTM1 cause the severe congenital myopathy called
myotubular myopathy [or X-linked centronuclear myopathy
(XLCNM); OMIM 310400] (16), while mutations in either the ac-
tive MTMR2 or the dead-phosphatase MTMR13 cause Charcot-
Marie-Tooth (CMT) peripheral neuropathies (CMT4B1, OMIM
601382 and CMT4B2, OMIM 604563, respectively) (17–19). In ad-
dition, putative mutations in MTMR5 (Sbf1) were linked to
CMT4B3 (OMIM 615284) and axonal neuropathy (20–22). Thus,
lack of one MTM is not fully compensated by its homologs,
despite the fact they are ubiquitously expressed. Moreover, the
related diseases affect different tissues. Of note, MTM1 and
MTMR2 are part of the same evolutionary sub-group based on
their sequence (13). Thus, this suggests uncharacterized tissue-
specific functions potentially reflecting different protein iso-
forms having specific activities or interactors. Here, we show
that there are two protein isoforms of MTMR2 and we studied
their in vivo functions in yeast and in mice. We report that only
the short MTMR2 isoform complements the yeast ymr1D mutant
phenotypes at a similar level as MTM1. Moreover, both MTMR2
isoforms ameliorate the myopathy phenotypes displayed by
Mtm1 knockout (KO) mice, and specifically the short MTMR2
isoform produced a better disease rescue.
Results
MTMR2 splicing variants are differentially expressed
and encode for long and short protein isoforms
Mutations in the MTMR2 gene are responsible for CMT neuropa-
thy (CMT4B1) whereas mutations in MTM1 lead to X-linked
centronuclear myopathy (XLCNM), suggesting that these two
ubiquitously expressed MTMs have distinct functions. Most tis-
sues contain more than a single isoform, thus their localization
and extent of expression could help explain their different func-
tions. In order to investigate MTMR2 function, we first defined its
tissue expression and isoforms. In mice, four MTMR2 mRNA iso-
forms (V1 to V4) have been previously reported in peripheral
nerves, potentially coding for 2 protein isoforms (Supplementary
Material, Fig. S1A and B) (23). Variants V2 to V4 differ from variant
V1 by the inclusion of alternative exons 1a and/or 2a leading to a
premature stop codon and unmasking an alternative start site in
exon 3. Variant V1 encodes a 643 amino acids (Aa) protein that
we named MTMR2-L (long) while the other isoforms code for a
571 Aa protein named MTMR2-S (short) that was previously de-
tected in various cell lines (23). The two protein isoforms differ
only in their translation start sites; MTMR2-S starts right before
the PH-GRAM domain while the MTMR2-L has an extended N-ter-
minal sequence without known homology to any protein domain
and that was not visible in the crystal structure (Fig. 1C;
Supplementary Material, Fig. S1B) (24,25). The expression level of
these isoforms was first investigated in human tissues through
mining the GTEx expression database encompassing data on 51
human tissues (26). Variant V1 is the major MTMR2 RNA in brain,
liver and spleen while variant V2 is predominant in the other tis-
sues. The different variants were only poorly expressed in skele-
tal muscle (Fig. 1A). In mouse, RT-PCR and Sanger sequencing
confirmed the existence of the four Mtmr2 mRNA variants (V1 to
V4) in tibialis anterior (TA) skeletal muscle of wild-type (WT) and
Mtm1 KO mice and in the liver (Supplementary Material, Fig. S1C
and D), suggesting that both MTMR2-L and MTMR2-S proteins are
present in skeletal muscle.
Short but not long MTMR2 isoform displays an
MTM1-like activity in yeast cells
To compare the cellular function of MTM1, MTMR2-L and
MTMR2-S proteins in vivo, we used heterologous expression of
these human MTMs in yeast cells. Yeast is a good model to
study phosphoinositide-dependent membrane trafficking as it
is conserved from yeast to higher eukaryotes (27). In yeast cells,
vacuole volume, morphology, acidity and membrane potential
are controlled by PtdIns(3,5)P2 that is produced through the
phosphorylation of PtdIns3P by Fab1/PIKfyve kinase. In fab1D
mutant cells, the vacuole is very large and unilobed owing to
low levels of PtdIns(3,5)P2 (15,28,29). On the contrary, ymr1D cells
lacking the unique yeast MTM have fragmented vacuoles owing
to excess of PtdIns(3,5)P2 and/or PtdIns3P (14), and this pheno-
type is complemented by the expression of the human MTM1
that induces a large vacuole phenotype (15). To determine
MTM1, MTMR2-L and MTMR2-S intracellular localization, we
overexpressed GFP-tagged fusions in ymr1D cells. MTM1-GFP
and MTMR2-S-GFP proteins were concentrated to a membrane
punctate structure adjacent to the vacuole (also positive for the
FM4-64 lipid dye), while MTMR2-L-GFP was mainly in the cyto-
plasm (Fig. 2C). We next assessed the vacuolar morphology
upon overexpression of either GFP-tagged or untagged human
3737Human Molecular Genetics, 2017, Vol. 26, No. 19 |
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/26/19/3736/3930117 by U
niversite de Strasbourg France user on 18 N
ovem
ber 2019
MTMs in ymr1D cells by staining the vacuolar membrane with
the lipophilic dye FM4-64 (Fig. 2B and C). To detect MTMR2 iso-
forms, a mouse monoclonal antibody was raised against
recombinant full length human MTMR2-L. This antibody was
validated on the transformed yeast protein extracts, and specifi-
cally recognized MTMR2-L and MTMR2-S (Fig. 2A). Vacuoles
were significantly enlarged upon expression of MTM1 or
MTMR2-S in ymr1D cells while they remained fragmented with
MTMR2-L. MTM1 and MTMR2-S induced a large vacuolar mor-
phology mimicking a fab1D phenotype owing to the high ex-
pression levels of these phosphatases (overexpression plasmid).
These results show that only the membrane localized MTM con-
structs rescued the vacuole morphology defects of ymr1D cells.
Since the vacuolar morphology reflects the PtdIns(3,5)P2 level
and as PtdIns(3,5)P2 is not abundant enough to be detected in
normal growth conditions (29), we quantified by mass assay the
level of PtdIns5P, the lipid produced by MTM phosphatase activ-
ity from PtdIns(3,5)P2 (Fig. 2F). PtdIns5P level was increased by
MTM1 and MTMR2-S overexpression in ymr1D cells, while
MTMR2-L had no effect. We also quantified the PtdIns3P MTM
substrate level, by counting the punctate structures that were
positive for DsRED-FYVE, a reporter for PtdIns3P-enriched mem-
branes (27) (Fig. 2D and E). Overexpression of MTM1 and
MTMR2-S significantly reduced PtdIns3P level while MTMR2-L
had no effect. However, previous data showed MTMR2-L had a
strong phosphatase activity in vitro (5,7), suggesting that the
cytoplasmic localization of this isoform in yeast cells does not
allow PPIn substrate dephosphorylation. In conclusion, only
MTMR2-S has a similar phosphatase activity and localization as
MTM1 in yeast cells, while MTMR2-L behaves differently.
Exogenous expression of MTMR2 short isoform in the
Mtm1 KOmice rescues muscle weight and force
similarly to MTM1 expression
To assess whether in mammals MTMR2-S is also functionally
closer to MTM1 compared with MTMR2-L, we overexpressed
human MTM1, MTMR2-L and MTMR2-S in the Mtm1 KO mouse
and analyzed different myopathy-like phenotypes. The
Figure 1. MTMR2 splicing isoforms are differentially expressed and encode for long and short protein isoforms. (A) Comparative expression of MTMR2 mRNA isoforms
V1 to V4 in 20 human tissues from GTEx database mining (top). Human MTMR2 V2 isoform contains additional exons 1a and 2a compared with V1, V3 contains exon 1a
and V4 contains exons 1a and 2b. Tissue expression of each isoform independently (bottom). (B) Protein domains of MTMR2-L encoded by V1 mRNA isoform, and
MTMR2-S encoded by the other isoforms, compared to MTM1.
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different MTMs were expressed from adeno-associated virus
(AAV) AAV2/1 under the control of the CMV promoter and the
recombinant virions were injected into the TA muscles of 2- to
3-week-old Mtm1 KO mice. The Mtm1 KO mice develop a
progressive muscle atrophy and weakness starting at 2–3 weeks
and leading to death by 8 weeks, the TA muscle being the most
affected muscle detected in this model (30,31). We have previ-
ously shown that AAV-mediated expression of MTM1 for
Figure 2. Short but not long MTMR2 isoform displays an MTM1-like activity. Exogenous expression of human MTM1 and MTMR2 long and short isoforms using the
high copy number plasmid 2m in ymr1D yeast cells. (A) Detection of exogenously expressed human myotubularins by western blot using anti-MTM1 or anti-MTMR2
antibodies, in two independents blots with the same samples. Wild-type (WT) and ymr1D yeast strains with empty vectors are used as controls. Pgk1p is used as a load-
ing control. This blot is representative of at least three independent experiments. (B) Quantification of vacuolar morphology in yeast cells over-expressing untagged
myotubularins. Three clones analyzed per constructs; the number of cells counted per clone is indicated above. Data represent mean6S.E.M. ****P<0.0001, ns, not sig-
nificant (ANOVA test). (C) Localization of GFP-tagged human myotubularins. Vacuole morphology is assessed by the lipophilic dye FM4-64 and Nomarski differential
contrast. ymr1D yeast cells and MTMR2-L expressing cells display a fragmented vacuole while MTM1 and MTMR2-S over-expressing cells have a large vacuole. Scale
bar 5 lm. (D) FYVE punctuated localization in yeast clones expressing untagged myotubularins and DsRED-tagged FYVE domain that specifically binds PtdIns3P. Scale
bar 5 lm. (E) PtdIns3P quantification by counting the number of FYVE-positive dots per cell, as represented in (D). PtdIns3P is decreased upon MTM1 and MTMR2-S ex-
pression but not with MTMR2-L. Data represent mean6S.E.M. *P< 0.05, **P<0.01 (ANOVA test). (F) PtdIns5P quantification by mass assay on total lipid extract from
yeast cells over-expressing untagged myotubularins. Three clones analyzed per constructs. Data represent mean6S.E.M. *P<0.05 (ANOVA test).
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4 weeks in the TA muscle, corrects the myopathy phenotype in
Mtm1 KO mice (15). Therefore to determine the impact of intro-
ducing MTMR2-L and MTMR2-S into Mtm1 KO mice, we followed
our previously described protocol for AAV injections (15), using
MTM1 as a positive control for the rescue, and empty AAV2/1 as
a disease control in the contralateral muscle. The MTM1,
MTMR2-L and MTMR2-S human MTMs were expressed in in-
jected TA, as revealed from anti-MTM1 and anti-MTMR2 west-
ern blot analyses (Fig. 3A). Endogenous MTMR2 proteins were
not detected in muscle injected with empty AAV, most likely
owing to the low level of endogenous expression (Fig. 3A).
Four weeks after AAV injection, the TA muscle weight of the
Mtm1 KO mice was decreased by 2.5-fold compared with WT mice,
both injected with empty AAV control. MTM1 or MTMR2-S expres-
sion in Mtm1 KO mice increased muscle mass significantly com-
pared with the empty AAV control (1.5-fold), contrary to MTMR2-L
(Fig. 3B). To address a potential hypertrophic effect of human
MTM1 or MTMR2 constructs in WT mice, TA muscle weight of in-
jected WT mice was quantified (Supplementary Material, Fig. S2).
No increased muscle mass was noted with any MTMs indicating
that the amelioration observed in the Mtm1 KO mice was not ow-
ing to a hypertrophic effect but to a functional rescue.
The Mtm1 KO mice displayed very weak muscle force com-
pared with WT mice, and all MTM constructs including MTMR2-
L improved the TA specific muscle force (Fig. 3C). Noteworthy, a
similar rescue was observed for MTM1 and MTMR2-S, signifi-
cantly above that observed for MTMR2-L injected muscles.
These results show that both MTMR2-L and MTMR2-S isoforms
improve the muscle weakness owing to loss of MTM1, and
MTMR2-S expression induces a rescue akin to that observed by
MTM1 gene replacement.
The MTMR2 isoforms rescue the histopathological
hallmarks of theMtm1 KOmouse
In the Mtm1 KO mice, TA injections of AAV2/1 carrying MTM1,
MTMR2-L or MTMR2-S increased muscle mass (except for
MTMR2-L) and force (Fig. 3). To analyze the rescue at the histo-
logical level, fiber size and nuclei localization were determined
(Fig. 4). Hematoxylin-eosin (HE) staining revealed increased fiber
size in AAV-MTM1 and AAV-MTMR2-S injected Mtm1 KO
muscles, compared to muscles treated with empty AAV or
MTMR2-L (Fig. 4A), even though we observed spatial heteroge-
neity in the muscle, with some regions still displaying smaller
atrophic fibers. Morphometric analysis revealed that among the
different MTMs tested, MTM1 induced a clear shift toward larger
fiber diameters compared with MTMR2 constructs and empty
AAV (Fig. 4C). A very significant difference (P< 0.0001) was ob-
served between AAV-MTM1 (mean 58.4%) and AAV-MTMR2-L
(mean 26.2%) in the percentage of muscle fibers having an area
above 800 mm2, whereas the difference was less significant
(P¼ 0.033) between MTM1 and MTMR2-S (39.8%) (Fig. 4D). Since
nuclei are abnormally located within muscle fibers in Mtm1 KO
mice, we analyzed the distribution of nuclei. Injection of MTM1,
MTMR2-S or MTMR2-L into the TA muscle of Mtm1 KO increased
significantly the percentage of well-positioned peripheral nuclei
compared with contralateral control muscles injected with
empty AAV (Fig. 4E). The succinate dehydrogenase (SDH) stain-
ing showed accumulation at the periphery and center in the
Mtm1 KO fibers (15), while it was greatly ameliorated upon ex-
pression of the different MTM constructs (Fig. 4B). These results
show that both MTMR2 isoforms were able to ameliorate the
Figure 3. The MTMR2 short isoform rescues muscle weight and force similarly
as MTM1 in Mtm1 KO myopathic mice. TA muscles from 2- to 3-week-old Mtm1
KO mice were injected with AAV2/1 expressing myotubularins and analyzed
4 weeks later. (A) Detection of exogenously expressed human myotubularins by
western blot using anti-MTM1 or anti-MTMR2 antibodies; GAPDH is used as a
loading control. Unspecific bands are indicated by a star. This blot is representa-
tive for each construct, and at least 10 muscles per construct were analyzed. (B)
Ratio of muscle weight of TA expressing human myotubularins compared with
the contralateral leg injected with empty AAV. MTMR2-S improved muscle mass
similarly as MTM1 while MTMR2-L had no effect. A value of 1 was set for the
Mtm1 KO mice injected with empty AAV. n>10. Data represents mean6S.E.M.
****P<0.0001, ns, not significant (ANOVA test). (C) Specific maximal force of TA
muscle (absolute maximal force (mN) relative to muscle mass (mg)). Both
MTMR2 isoforms improved muscle force. n>7. Data represent means6S.E.M.
**P< 0.01, ****P<0.0001; ns, not significant (ANOVA test).
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histopathological hallmarks of the MTM1 myopathy, where
MTMR2-S was more effective.
MTMR2 isoforms rescueMtm1 KOmuscle
disorganization and normalize PtdIns3P levels
Patients with myotubular myopathy and the Mtm1 KO mice dis-
play an intracellular disorganization of their muscle fibers at the
ultrastructural level (30,32). To determine the organization of the
contractile apparatus and triads, the ultrastructure of the differ-
ent injected TA muscles was assessed by electron microscopy. As
previously published, we observed Z-line and mitochondria mis-
alignment, thinner sarcomeres and lack of well-organized triads
in the Mtm1 KO muscle injected with empty AAV (15) (Fig. 5A).
Expression of MTM1 and both MTMR2 isoforms improved these
different phenotypes, with the observation of well-organized tri-
ads with two sarcoplasmic reticulum cisternae associated with a
central transverse-tubule (T-tubule) in muscles injected with
MTM1, MTMR2-L or MTMR2-S (Fig. 5A). Moreover, AAV-mediated
expression of MTM1, MTMR2-L and MTMR2-S increased the num-
ber of triads per sarcomere back to almost WT levels, with a bet-
ter effect for MTMR2-S compared with MTMR2-L (Fig. 5B).
Figure 4. Both long and short MTMR2 isoforms improve the histological hallmarks of the Mtm1 KO mouse. TA muscles from 2- to 3-week-old Mtm1 KO mice were injected
with AAV2/1 expressing myotubularins and analyzed 4 weeks later. (A) Hematoxylin-eosin staining of TA muscle sections. Scale bar 100 mm. (B) Succinate dehydrogenase
(SDH) staining of TA muscle sections. Scale bar 100 mm. (C) Quantification of fiber area. Fiber size is grouped into 200 mm2 intervals and represented as a percentage of total
fibers in each group. n> 1000 for 8 mice. (D) Percentage of fibers above 800 mm2. n>8. Data represent mean6S.E.M. *P<0.05, ***P<0.001, ****P< 0.0001 (ANOVA test). The
value for WT is statistically different from all Mtm1 KO injected groups. (E) Nuclei positioning in TA muscle. Percentage of well-positioned peripheral nuclei. n> 6 animals.
Data represent mean6S.E.M. ***P<0.001, ****P<0.0001 (ANOVA test). The value for WT is statistically different from all Mtm1 KO injected groups.
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In yeast, only MTMR2-S but not MTMR2-L regulated the
PtdIns3P MTM substrate level, as well as the one of PtdIns(3,5)P2
as assessed by vacuolar morphology (Fig. 2B). To determine
whether the rescuing capacity of MTMR2 in mice was linked to
its enzymatic activity, we quantified the intracellular levels of
PtdIns3P in the AAV empty, MTM1, MTMR2-L and MTMR2-S
injected TA muscles of Mtm1 KO mice (Fig. 6A). PtdIns3P level
was 2.3-fold higher in empty AAV injected Mtm1 KO muscle
than in WT muscle, reflecting the impact of the loss of MTM1 on
its PtdIns3P lipid substrate. Upon expression of MTM1, the
PtdIns3P level decreased to WT levels, reflecting the in vivo
phosphatase activity of MTM1. Both MTMR2 isoforms induced a
decrease in PtdIns3P level when expressed in the Mtm1 KO
mice, however only the short MTMR2-S isoform normalized
PtdIns3P to WT levels. These results show that MTMR2 displays
an in vivo enzymatic activity in muscle. Moreover, the MTMR2
catalytic activity correlates with the rescue observed by exoge-
nous expression in the Mtm1 KO myopathic mice.
Taken together, the results in Mtm1 KO mice expressing
MTM1 or MTMR2 isoforms show that the different phenotypes
associated with the myopathy including reduced muscle force,
myofiber atrophy, nuclei mispositioning, sarcomere and triad
disorganization and increased PtdIns3P levels, were ameliorated
compared with the control muscle injected with empty AAV
(Table 1). Noteworthy, as observed in yeast studies, the shorter
isoform MTMR2-S provided a better rescue than MTMR2-L, and
was often comparable to MTM1.
Expression of the MTMR2 short isoform is reduced in
theMtm1 KOmice muscles
Based on the GTEx expression database, the different MTMR2
mRNA variants (V1 to V4) producing these two MTMR2 protein
isoforms are expressed in different tissues, with a low expres-
sion level in the skeletal muscle (Fig. 1). However, despite their
strong rescue properties upon overexpression in TA muscles of
Mtm1 KO mice (Figs 3–5 and 6A; Table 1), endogenous expres-
sion of MTMR2 variants does not compensate for the loss of
MTM1 function in the myopathy patients. To help understand
the difference in rescue observed between the MTMR2-L and -S
isoforms, we quantified mRNA levels of the different Mtmr2 var-
iants (V1 to V4) in TA muscles of Mtm1 KO compared with WT
mice (Fig. 6B). The results show that Mtmr2 mRNA total level
was decreased in Mtm1 KO muscles by 2-fold. This was mainly
owing to a strong decrease in the V2 and V3 transcripts encod-
ing the MTMR2-S isoform, while the level of the V1 transcript
coding for MTMR2-L remained statistically unchanged between
Mtm1 KO and WT mice. Note that these decrease were not ob-
served in Supplementary Material, Fig. S1D since it presents a
conventional RT-PCR that does not allow quantification. A simi-
lar downregulation of V2 and V3 transcripts encoding
the MTMR2-S isoform was observed in XLCNM patient muscles
(Fig. 6C). These data suggest that the lack of compensation of
MTM1 loss by endogenous MTMR2 is linked to the low expres-
sion level of MTMR2 associated with MTMR2-S decreased level
in skeletal muscles. Alternatively, this could be linked to the
low level of MTMR2 proteins in the muscle.
Discussion
Here we aimed to determine functional specificities and redun-
dancies of MTM1 and MTMR2 MTMs belonging to the same fam-
ily of proteins, but whose mutations result in different diseases
affecting different tissues, a myopathy and a neuropathy, re-
spectively. We also tested their abilities to compensate for each
other as a potential novel therapeutic strategy. Using molecular
investigations and overexpression of these human MTMs in
yeast cells and in the skeletal muscle of the Mtm1 KO myopathic
mice, we characterized two MTMR2 isoforms with different
Figure 5. MTMR2 isoforms rescue the muscle ultrastructure and triad morphol-
ogy of the Mtm1 KO muscles. TA muscles from Mtm1 KO mice were injected with
AAV2/1 expressing myotubularins. (A) Electron microscopy pictures displaying
sarcomere, mitochondria and triad organization. Scale bar 1 mm. Representative
triads are displayed in the zoom square. (B) Quantification of the number of
well-organized triads per sarcomere. n> 20 images for 2 mice each. All muscles
expressing myotubularins were significantly different from the Mtm1 KO. Data
represent mean6S.E.M. *P<0.05, ****P<0.0001 (ANOVA test).
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catalytic activities linked to their ability to access their PPIn sub-
strates. Moreover, we showed that overexpression of MTMR2
rescues the myopathy owing to MTM1 loss and that compared
with MTMR2-L, the short MTMR2-S isoform displayed a better
PtdIns3P phosphatase activity in yeast and in mice, correlating
with better rescuing properties in MTM-depleted ymr1D yeast
cells and in Mtm1 KO mice. The fact that MTMR2-L partially im-
proved the phenotypes of Mtm1 KO mice despite performing
poorly in yeast assays could be owing to a lack of regulatory pro-
teins in the yeast heterologous system.
MTMR2 Isoforms and Functions
There are four naturally occurring MTMR2 mRNA variants in hu-
man and mice encoding two protein isoforms (MTMR2-L and -
S), differing by a 72 Aa extension at the N-terminal. MTMR2-S
displayed a higher phosphatase activity than MTMR2-L in vivo
in yeast and mouse, suggesting the N-terminal is important for
the regulation of MTMR2 function. The phosphorylation of the
serine 58, within this N-terminal extension, was shown to be
important for MTMR2 endosomal membrane localization and
catalytic function (33,34). Indeed, the MTMR2-S58A phosphory-
lation-deficient mutant was localized to membrane structures
and was active towards PtdIns3P, contrary to the phosphomi-
metic mutant MTMR2-S58E (33,34). Here, we show that the
MTMR2-S protein lacking the N-terminal sequence
encompassing the S58 phosphorylated residue is concentrated
to membranes when expressed in yeast (Fig. 2B) and is more ac-
tive towards PtdIns3P compared with MTMR2-L in yeast (Fig.
2D) and in murine muscles (Fig. 6A). The N-terminal extension
of MTMR2 was not resolved in the crystallographic structure,
supporting the hypothesis that it can adopt different conforma-
tions and might regulate MTMR2 functions (24,25). These results
show that there are two forms of MTMR2, MTMR2-S mainly
membrane localized and with high phosphatase activity in vivo
and MTMR2-L whose membrane localization is dependent on
phosphorylation at the S58 residue. Interestingly, in brain ex-
pression is biased toward the MTMR2 V1 variant coding for
MTMR2-L (Fig. 1). The S58 phosphorylation is mediated by Erk2
kinase whose expression in brain is higher than in other tissues,
correlating with MTMR2-L expression (GTEx database).
Functional Redundancy and Compensation within
MTMs
There are 14 MTMs mostly ubiquitously expressed in human
tissues, but the loss of MTM1 leads specifically to a severe con-
genital myopathy. This reveals that MTM1 homologs, notably
the closer MTMR2 homolog, do not compensate for the lack of
MTM1 in the skeletal muscles when expressed at endogenous
levels. We provide evidence that MTMR2-S is downregulated in
the skeletal muscles of the myopathic Mtm1 KO mice and
Figure 6. The MTMR2-S short isoform is reduced in the Mtm1 KO mouse and its overexpression normalizes PtdIns3P level. (A) Quantification of PtdIns3P level by com-
petitive ELISA in TA muscles from Mtm1 KO mice expressing different myotubularins and in WT muscles. n>3 mice. Data represent mean6S.E.M. *P<0.05, **P<0.01,
***P<0.001 (ANOVA test). PtdIns3P levels in Mtm1 KO muscles expressing the different myotubularins are not statistically different from the WT controls.
(B) Quantification by qRT-PCR of Mtmr2 isoforms (V1 to V4) in the TA muscle of Mtm1 KO mice compared with WT mice. n>6. Each isoform is presented as an indepen-
dent ratio, with a value of 1 set for expression in WT mice. Data represent mean6 s.d. **P<0.01, ***P<0.001, ****P<0.0001; ns, not significant (Student’s t-test).
(C) Quantification by qRT-PCR of MTMR2 isoforms (V1 to V4) in muscles of patients mutated in MTM1 compared with controls; n¼3. Each isoform is presented as an in-
dependent ratio, with a value of 1 set for expression in control patients. Data represent mean6 s.d. The P value is indicated for each isoform (Student’s t-test).
Table 1. Rescuing effects of MTM1 and MTMR2 isoforms on several hallmarks of myotubular myopathy
Mtm1 KOþempty AAV Mtm1 KOþMTM1 Mtm1 KOþMTMR2-L Mtm1 KOþMTMR2-S WTþempty AAV
Muscle weight  þþ – þþ þþþ
Muscle force  þþ þ þþ þþþ
Fiber size  þþ þ þ þþþ
Nuclei positioning  þþ þþ þþ þþþ
Number of well-organized
triads/sarcomere
 þþ þ þþ þþþ
PtdIns3P level  þþþ þþ þþþ þþþ
‘þ,þþ,þþþ’: increasing rescuing ability of myotubularins, ranging from ‘’: no rescue to ‘þþþ’: WT phenotype.
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XLCNM patients. Moreover, compared with brain and other tis-
sues, the expression of MTMR2 transcripts is low in skeletal
muscles. Altogether this suggests that this low expression of
MTMR2 in muscle exacerbated by its downregulation in the my-
opathy mouse model and in XLCNM patient muscles is the basis
for the lack of compensation. Indeed, the MTMR2-S improves
better both functional and structural myopathic phenotypes
and is more significantly downregulated than MTMR2-L in the
myopathic muscles. This reveals that the molecular basis for
the functional difference between MTM1 and MTMR2 resides in
the N-terminal extension upstream the PH-GRAM domain, with
the MTMR2-S lacking this extension displaying similar in vivo
functions as MTM1 in yeast and in mice. Removal of this N-ter-
minal extension in the native MTMR2-L isoform converts
MTMR2 activity into an MTM1-like activity.
The ability of MTMR2-S to rescue myopathic phenotypes in
Mtm1 KO mice after muscle expression could be owing to the
observed normalization of PtdIns3P levels. A previous study in
the drosophila mutant of the MTM1 ortholog (mtm) showed that
impairment of class II PtdIns 3-kinase prevents the phenotypes
and death of the mtm mutant (35). More recently, two studies
proposed that normalization of PtdIns3P levels through downre-
gulation of class II PtdIns 3-kinase PIK3C2B or broad inhibition
of PtdIns 3-kinase activity and thus PtdIns3P production by
Wortmannin, rescues the muscle phenotypes of Mtm1 KO mice
(36,37). Other therapeutic proof-of-concepts have been reported
that do not target PPIn normalization, such as downregulation/
normalization of DNM2 (31), expression of catalytic dead MTM1-
C375S (15) or inhibition of autophagy (38). Thus, it is also possi-
ble that the exogenously expressed MTMR2-L or MTMR2-S act in
a PPIn-independent way to improve the Mtm1 KO phenotypes.
Of note, the MTM1-C375S dead-phosphatase mutant does not
improve the triad shape that is well rescued upon expression of
active MTM1 or MTMR2-S, supporting an important role of PPIn
at the triad.
MTMR2 as a Novel Therapeutic Target for Myotubular
Myopathy
Here we provide the proof-of-concept that MTMR2 could be
used as a therapeutic target. Intramuscular AAV transduction of
human MTMR2 into Mtm1 KO mice greatly improved the pheno-
types, supporting the rescue is cell autonomous in muscle.
While this actual protocol aimed to investigate the cell autono-
mous compensation by MTMR2 through intramuscular injec-
tion, it was not possible to determine the extent of the rescue
and the long-term potential of MTMR2-mediated rescue as
Mtm1 KO mice die at around 2 months most probably from re-
spiratory failure and feeding defect. Complementation of myo-
tubular myopathy by recombinant MTM1 or MTM1 re-expressed
from injected AAVs were previously proposed as potential ther-
apies (39,40). Expression of MTMR2 in muscle could be an attrac-
tive alternative that may not elicit immune response against
the transgene, as the majority of patients with myotubular my-
opathy have a strong decrease or a total loss of MTM1 (41,42).
Our data support that MTMR2-S isoform has a better rescuing
ability than the main described MTMR2-L isoform and is a natu-
rally occurring variant, including in muscle. Since MTMR2-S
transcripts are decreased in the Mtm1 KO muscles, a potential
strategy will be to promote their expression by modulation
of MTMR2 alternative splicing or exogenous expression.
Alternatively, since MTMR2 ameliorates the myopathy owing to
the lack of MTM1, it would be interesting to test whether MTM1
delivery may be a therapeutic option for CMT4B caused by
MTMR2 mutations.
Materials and Methods
Ethics statement
Mice were humanely killed by cervical dislocation after injec-
tion of pentobarbital, according to national and European legis-
lations on animal experimentation.
Sample collection was performed with written informed
consent from the patients or parents according to the declara-
tion of Helsinki. The three XLCNM patients had the following
mutations in MTM1: [c.445-49_445-4 del], [c.523A>G in exon 7,
p.Arg175Gly] and [c.145_161del17 in exon 4, p.Val49Phe fs*6].
Plasmids and constructs
The human MTM1 (1812 bp, 603 Aa) and MTMR2-L (1932 bp, 643
Aa) ORFs were cloned into the pDONR207 plasmid (Invitrogen,
Carlsbad, CA, USA) to generate entry clones (pSF108 and pSF98,
respectively). The pDONR207-MTMR2-S (1716 bp, 571 Aa,
pSF101) has been obtained by site-directed mutagenesis on
MTMR2-L into the pSF98 vector, to delete the 216 first nucleo-
tides corresponding to the 72 first amino acids. Gateway system
(Invitrogen) was used to clone the different MTM constructs
into yeast destination expression vectors pAG424GPD-ccdB-
EGFP (43) and pVV200 (44) obtained from the European
Saccharomyces cerevisiae Archive for Functional Analysis
EUROSCARF, or into a pAAV-MCS vector (CMV promoter). All
constructs were verified by sequencing. The pCS211 DsRED-
FYVE plasmid was previously described (27). The AAV Helper-
Free system was purchased from Stratagene (La Jolla, CA) (cata-
log number 240071). pXR1 (AAV1) plasmid was a gift from Jude
Samulski at the Gene Therapy Center, the University of North
Carolina at Chapel Hill.
Antibodies
Primary antibodies used were rabbit polyclonal anti-MTM1
(2827), mouse monoclonal anti-MTMR2 (4G3), mouse monoclo-
nal anti-phosphoglycerate Kinase 1 (PGK1, Invitrogen) and
mouse monoclonal anti-glyceraldehyde-3-phosphate dehydro-
genase (anti-GAPDH, Chemicon by Merk Millipore, Darmstadt,
Germany). Anti-MTM1 and anti-MTMR2 antibodies were made
onsite at the antibodies facility of the Institut de Ge´ne´tique et
Biologie Mole´culaire et Cellulaire (IGBMC). Anti-MTMR2 antibod-
ies were raised against full length human MTMR2 and validated
in this study using transfected COS-7 cells. Secondary antibod-
ies against mouse and rabbit IgG, conjugated with horseradish
peroxidase (HRP) were obtained from Jackson ImmunoResearch
Laboratories (West Grove, PA, USA).
In vivomodels
The S. cerevisiae ymr1D (MATa, ura3-52, leu2-3,112, his3-D200,
trp1-D901, lys2-801, suc2-D9 ymr1::HIS3) (14) and WT (MATa,
his3D1, leu2D0, lys2D0, ura3D0) strains were grown at 30 C in
rich medium (YPD): 1% yeast extract, 2% peptone, 2% glucose or
synthetic drop-out medium (SC): 0.67% yeast nitrogen base
without amino acids, 2% glucose and the appropriate amino
acids mixture to ensure plasmid maintenance. We did not use
the ymr1D (MATa, his3D1, leu2D0, lys2D0, ura3D0, ymr1::KanMX)
in the BY4742 background from the yeast systematic deletion
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collection, because it does not have the ymr1D phenotype de-
scribed by Scott D Emr’s laboratory (14).
In this study, we used WT and Mtm1 KO 129 PAS mice. The
Mtm1 KO mice are characterized by a progressive muscle atro-
phy and weakness starting at 2–3 weeks and leading to death by
8 weeks (30). Animals were housed in a temperature-controlled
room (19–22 C) with a 12:12-h light/dark cycle.
Bioinformatics analysis
Expression levels of MTMR2 mRNA isoforms was obtained by
mining the Genotype-Tissue Expression (GTEx, www.gtexpor
tal.org/home/) database, which has been built by systematic
RNA-sequencing using samples of 51 different tissues from
hundreds of donors and two transformed cell types in culture.
We then used this data to calculate the relative expression of
MTMR2 mRNA isoforms in the 20 most relevant tissues, and to
create a heat map underlining in which tissue a specific isoform
is the most/least expressed.
Alignment of the N-terminal part of MTM1, MTMR2-L and
MTMR2-S was done using Jalview (www.jalview.org/) and align-
ing amino acids were identified by Clustalx color coding.
Expression analysis
Total RNA was purified from TA muscle and liver of 7-week-old
WT and Mtm1 KO mice, or from muscle biopsies of XLCNM pa-
tients and controls, using trizol reagent (Invitrogen) according
to the manufacturer’s instructions. cDNAs were synthesized
from 500 ng of total RNA using Superscript II reverse transcrip-
tase (Invitrogen) and random hexamers.
PCR amplification of 1/10 diluted cDNA from TA muscle and
liver was performed using a forward primer from the 5’-UTR of
MTMR2: 5’-AGCGGCCTCCAGTTTCTCGCGC-3’ and a reverse pri-
mer from exon 3: 5’-TCTCTCCTGGAAGCAGGGCTGGTTCC-3’, for
35 cycles of amplification at 72 C (and 65 C as melting tempera-
ture) and 30 min of final extension at 72 C, as previously de-
scribed (23). The products were analyzed on a 2% agarose gel,
each band has been purified using Nucleospin Gel and PCR
cleanup kit (Macherey-Nagel, Du¨ren, Germany), then cloned into
a pJet2.1 vector using the CloneJet PCR cloning kit (ThermoFisher
Scientific, Waltham, MA, USA), and sequenced by Sanger.
Quantitative PCR amplification of 1/10 diluted cDNAs from
mouse TA muscles or human muscle biopsies was performed
on Light-Cycler 480 II instrument (Roche, Basel, Swiss) using
53 C as melting temperature. Specific sets of primers were used
for each mouse MTMR2 isoform: forward 5’-GACTCACTGTCC
AGTGCTTC-3’ and reverse 5’-CCTCCCTCAGGACCCTCA-3’ for
mouse V1, forward 5’-GACTCACTGTCCAGTGCTTC-3’ and
reverse 5’-CAGCTGGGCACTCCCTCA-3’ for mouse V2, forward
5’-AAGATAAAACATCTCAAAAATTATAATTGCTTC-3’ and re-
verse 5’-CAGCTGGGCACTCCCTCA-3’ for mouse V3, forward 5’-
AAGATAAAACATCTCAAAAATTATAATTGCTTC-3’ and reverse
5’-GACTCACTGTCCAGTGCTTC-3’ for mouse V4. Another set of
primers (forward 5’-TCCTGTGTCTAATGGCTTGC-3’ and reverse
5’-AACCAAGAGGGCAGGATATG-3’) amplifying a sequence com-
mon to all mouse isoforms has been used to quantify total
mouse MTMR2. Other specific sets of primers were used for
each human MTMR2 isoform: forward 5’-ACTCCTTGTCCAG
TGCCTC-3’ and reverse 5’-GACTCCCTCAGGACCCTC-3’ for hu-
man V1, forward 5’-AAGATAAAACATCTCAAAAATTATAATT
GCCTC-3’ and reverse 5’-GACTCCCTCAGGACCCTC-3’ for human
V2, forward 5’-AAGATAAAACATCTCAAAAATTATAATTGCCTC-
3’ and reverse 5’-GAGCGAGACTCCCTCCTC-3’ for human V3, for-
ward 5’-AAGATAAAACATCTCAAAAATTATAATTGCCTC-3’ and
reverse 5’-CTGGACTGCATGGGCCTC-3’ for human V4. Another
set of primers (forward 5’-TTTCCTGTCTCTAATAACCTGCC-3’
and reverse 5’-CCAGGAGGGCAGGGTATG-3’) amplifying a se-
quence common to all human isoforms has been used to quan-
tify total human MTMR2. For all qPCR, the HPRT gene
expression was used as control because of the non-variation in
its expression between control and XLCNM muscles.
Western blot
Total proteins were extracted from yeast cells (OD600nm ¼ 0.5–0.9,
minimum three clones per construct) by TCA precipitation and
NaOH lysis (45), and from TA muscles (minimum 10 muscles per
construct) by homogenization in RIPA buffer using a tissue ho-
mogenizer (Omni TH, Kennesaw, GA, USA). Protein lysates were
analyzed by SDS-PAGE and western blotting on nitrocellulose
membrane. Proteins were detected using primary antibody (anti-
MTM1 1/500, anti-MTMR2 1/1000, anti-PGK1 1/1000 and anti-
GAPDH 1/1000) followed by incubation with the secondary anti-
body coupled to HRP, and extensive washing. Membranes were
revealed by ECL chemiluminescent reaction kit (Supersignal west
pico kit, ThermoFisher Scientific).
Yeast phenotyping
ymr1D yeast cells were transformed using the LiAc-PEG method
(46) by yeast expression plasmids pAG424GPD-ccdB-EGFP (2m,
GFP tag at C-ter) or pVV200 (2m, no tag) containing MTM1,
MTMR2-L or MTMR2-S cDNA. Yeast cells transformed by empty
plasmids were used as controls.
For vacuole staining, 1 OD600nm unit of cells was harvested
by a 500g centrifugation for 1 min, incubated in 50 ml YPD me-
dium with 2 ml FM4-64 (200 mM, Invitrogen) for 15 min at 30 C,
prior washing with 900 ml YPD and chasing by incubation at
30 C for 10 min followed by a second wash in SC complete me-
dium, the stained living yeast cells were observed by fluorescent
microscopy. Between 100 and 600 cells per clone (three different
clones per construct) were counted and classified into 2 catego-
ries: large or medium unilobar vacuole, and small or fragmented
vacuole.
For PtdIns3P quantification, yeast cells were co-transformed
by a pVV200 plasmid (empty or containing MTM1, MTMR2-L or
MTMR2-S cDNA) and the pCS211 plasmid expressing the DsRED-
FYVE reporter for PtdIns3P-enriched membrane structures (27).
After fluorescence microscopy, the number of dots per cell was
quantified on minimum 100 cells per clone (2 different clones
per construct).
For PtdIns5P quantification, yeast ymr1D cells producing the
different MTM1 and MTMR2 constructs were grown to exponen-
tial phase. Lipid extraction was done as described in Hama et al.
on 200 OD600nm units of cells (47). Quantification of the
PtdIns(5)P level was performed as described by Morris et al. (48)
and the results were normalized based on the total lipid
concentration.
All fluorescence microscopy observations were done with
100/1.45 oil objective (Zeiss) on a fluorescence Axio Observer
D1 microscope (Zeiss) using GPF or DsRED filter and DIC optics.
Images were captured with a CoolSnap HQ2 photometrix cam-
era (Roper Scientific) and treated by ImageJ (Rasband W.S.,
ImageJ, U. S. National Institutes of Health, Bethesda, MD, USA,
http://imagej.nih.gov/ij/; date last accessed July 11, 2017).
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PtdIns3P quantification by ELISA in muscle extracts
PtdIns3P Mass ELISAs were performed on lipid extracts from
whole TA muscle preparations according to the manufacturer’s
recommendations and using the PtdIns3P Mass ELISA kit
(Echelon Biosciences, Salt Lake City, UT, USA). TA muscles from
7-week-old WT of Mtm1 KO mice were weighed, grinded into a
powder using a mortar and pestle under liquid nitrogen and
then incubated in ice cold 5% TCA to extract lipids. Extracted
lipids were resuspended in PBS-T with 3% protein stabilizer and
then spotted on PtdIns3P Mass ELISA plates in duplicates.
PtdIns3P levels were detected by measuring absorbance at
450 nm on a plate reader. Specific amounts were determined by
comparison of values to a standard curve generated with known
amounts of PtdIns3P.
AAV production
rAAV2/1 vectors were generated by a triple transfection of AAV-
293 cell line with pAAV2-insert containing the insert under the
control of the CMV promoter and flanked by serotype-2 inverted
terminal repeats, pXR1 containing rep and cap genes of AAV
serotype-1, and pHelper encoding the adenovirus helper func-
tions. Viral vectors were purified and quantified by real time
PCR using a plasmid standard pAAV-eGFP. Titers are expressed
as viral genomes per ml (vg/ml) and rAAV titers used here were
5–71011 vg/ml.
AAV transduction of TAmuscles of WT andMtm1
KOmice
Two- to 3-week-old WT or Mtm1 KO male 129PAS mice were
anesthetized by intraperitoneal injection of 5 ml/g of ketamine
(20 mg/ml; Virbac, Carros, France) and xylazine (0.4%, Rompun;
Bayer, Wuppertal, Germany). TA muscles were injected with
20 ml of AAV2/1 preparations or sterile AAV2/1 empty vector.
Four weeks later, mice were anesthetized and the TA muscle
was either functionally analyzed (as described below), or di-
rectly dissected and frozen in nitrogen-cooled isopentane for
histology, or fixed for electron microscopy (as described below).
Functional analysis of the muscle
Muscle force measurements were evaluated by measuring in
situ muscle contraction in response to nerve and muscle stimu-
lation, as described previously (31). Animals were anesthetized
by intraperitoneal injection of pentobarbital sodium (50 mg/kg).
The distal tendon of the TA was detached and tied with a silk
ligature to an isometric transducer (Harvard Bioscience,
Holliston, MA, USA). The sciatic nerve was distally stimulated,
response to tetanic stimulation (pulse frequency of 50–143 Hz)
was recorded, and absolute maximal force was determined.
After contractile measurements, the animals were sacrificed by
cervical dislocation. To determine specific maximal force, TA
muscles were dissected and weighed.
Histology
Transverse cryosections (9 mm) of mouse TA skeletal muscles
were stained with hematoxylin and eosin (HE) or SDH and
viewed with a NanoZoomer 2.0HT slide scanner (Hamamatsu,
Hamamatsu city, Japan). Fiber area was analyzed on HE sec-
tions, using the RoiManager plugin of ImageJ image analysis
software. The percentage of peripheral nuclei was counted us-
ing the cell counter plugin of ImageJ image analysis software.
Electron microscopy
TA muscles of anesthetized mice were fixed with 4% PFA and
2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.2) and pro-
cessed as described (49). Ratio of triads/sarcomere was calcu-
lated by dividing the number of triad structures identified by
the total number of sarcomeres present on the section (2 mice
per genotype, minimum 10 fibers analyzed per mice, minimum
20 triads per fiber).
Statistical analysis
Data are mean6S.E.M. or 6SD as noted in the figure legend.
Statistical analysis was performed using one-way ANOVA fol-
lowed by Tukey’s multiple comparisons test for all data except
for the expression analysis (Fig. 6B and C) where an unpaired
two-tailed Student’s t test was performed. A P value <0.05 was
considered significant.
Supplementary Material
Supplementary Material is available at HMG online.
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